Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVEONASDAQ:ENLVNASDAQ:IFRXNASDAQ:ORMPNASDAQ:PTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsENLVEnlivex Therapeutics$1.18+4.0%$1.03$0.81▼$1.76$27.91M0.79129,533 shs141,087 shsIFRXInflaRx$0.81-0.7%$1.20$0.71▼$2.82$53.87M1.29289,375 shs56,884 shsORMPOramed Pharmaceuticals$2.18+1.1%$2.20$1.82▼$3.09$89.05M1.59142,022 shs18,026 shsPTIProteostasis Therapeutics$11.24$0.87▼$2.72$37.57M1.161.04 million shs9,405 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ENLVEnlivex Therapeutics0.00%-2.08%+26.34%+32.32%-11.65%IFRXInflaRx0.00%-0.35%-5.29%-20.30%-50.61%ORMPOramed Pharmaceuticals0.00%+1.58%-4.21%+4.00%-14.02%PTIProteostasis Therapeutics0.00%0.00%0.00%0.00%+22.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AENLVEnlivex Therapeutics3.2061 of 5 stars3.75.00.00.00.00.80.6IFRXInflaRx2.7295 of 5 stars3.55.00.00.00.01.70.6ORMPOramed Pharmaceuticals0.4339 of 5 stars0.03.00.00.01.00.80.6PTIProteostasis TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVEOAVEO Pharmaceuticals 0.00N/AN/AN/AENLVEnlivex Therapeutics 3.33Buy$10.00751.06% UpsideIFRXInflaRx 3.00Buy$6.60719.88% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/APTIProteostasis Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PTI, IFRX, ORMP, ENLV, and AVEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025IFRXInflaRxRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$2.005/29/2025IFRXInflaRxOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$6.00 ➝ $3.005/8/2025IFRXInflaRxOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.004/29/2025IFRXInflaRxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.004/21/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28ENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.00 per shareN/AIFRXInflaRx$180K300.22N/AN/A$1.13 per share0.71ORMPOramed Pharmaceuticals$1.34M66.58N/AN/A$3.61 per share0.60PTIProteostasis Therapeutics$5M0.00N/AN/A$1.22 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/AENLVEnlivex Therapeutics-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)IFRXInflaRx-$49.85M-$0.82N/AN/AN/AN/A-64.17%-53.39%8/6/2025 (Estimated)ORMPOramed Pharmaceuticals-$19.06M-$0.44N/AN/AN/AN/A-11.34%-10.73%8/13/2025 (Estimated)PTIProteostasis Therapeutics-$59.13M-$1.16N/AN/AN/AN/A-75.39%-55.04%N/ALatest PTI, IFRX, ORMP, ENLV, and AVEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q1 2025ENLVEnlivex Therapeutics-$0.16-$0.15+$0.01-$0.15N/AN/A5/15/2025Q1 2025ORMPOramed Pharmaceuticals-$0.03-$0.19-$0.16-$0.19N/A$2.00 million5/7/2025Q1 2025IFRXInflaRx-$0.18-$0.14+$0.04-$0.14$0.03 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/APTIProteostasis TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVEOAVEO Pharmaceuticals0.942.372.35ENLVEnlivex TherapeuticsN/A7.207.20IFRXInflaRxN/A5.284.86ORMPOramed PharmaceuticalsN/A23.9423.94PTIProteostasis TherapeuticsN/A6.696.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVEOAVEO Pharmaceuticals49.95%ENLVEnlivex Therapeutics1.02%IFRXInflaRx42.39%ORMPOramed Pharmaceuticals12.73%PTIProteostasis Therapeutics16.64%Insider OwnershipCompanyInsider OwnershipAVEOAVEO Pharmaceuticals3.29%ENLVEnlivex Therapeutics12.28%IFRXInflaRx16.30%ORMPOramed Pharmaceuticals13.70%PTIProteostasis Therapeutics4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableENLVEnlivex Therapeutics7023.65 million20.75 millionOptionableIFRXInflaRx6067.13 million56.19 millionOptionableORMPOramed Pharmaceuticals1040.85 million35.25 millionOptionablePTIProteostasis Therapeutics4452.19 millionN/ANot OptionablePTI, IFRX, ORMP, ENLV, and AVEO HeadlinesRecent News About These CompaniesUnlocking proteostasis: A new frontier in the fight against neurodegenerative diseases like Alzheimer'sJanuary 3, 2025 | msn.comProteostasis modulates gene dosage evolution in antibiotic-resistant bacteriaOctober 31, 2024 | elifesciences.orgEDELE1 maintains muscle proteostasis to promote growth and survival in mitochondrial myopathyOctober 8, 2024 | embopress.orgEIslamabad on red alert as PTI all set to hold rally todaySeptember 9, 2024 | thenews.com.pkT‘PTI was not a party in reserved seats case’: SC judges issue dissenting opinionAugust 9, 2024 | tribune.com.pkTHarness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board ChairApril 24, 2024 | globenewswire.comNews From PTIApril 11, 2024 | health.economictimes.indiatimes.comPTI files petition in ECP for disqualification of Faryal TalpurApril 8, 2024 | radio.gov.pkRSC accepts ECP’s appeal, strips PTI of ‘bat’ symbolMarch 25, 2024 | radio.gov.pkRIndependent candidates continue to join PTI in center, PunjabMarch 12, 2024 | radio.gov.pkRPeshawar High Court lifts stay on ECP verdict nullifying PTI’s intra-party pollJanuary 30, 2024 | radio.gov.pkRExperts hail decision of ECP that PTI received funding from prohibited sourcesJanuary 13, 2024 | radio.gov.pkRFormer PTI Chairman admits recent article in Economist not written by him, AI generatedJanuary 13, 2024 | radio.gov.pkRECP declares PTI’s intra-party polls as null and voidJanuary 10, 2024 | radio.gov.pkRQureshi barred, many PTI leaders cleared to contest pollsJanuary 8, 2024 | pakistantoday.com.pkPPakistan’s ex-PM Imran and PTI party most popular in the country: PollJanuary 4, 2024 | gulftoday.aeGAs scrutiny ends, PTI faces ‘unprecedented wave’ of rejections of nominationsJanuary 1, 2024 | pakistantoday.com.pkPPTI berates ECP over irresponsible, nonsensical statement regarding judiciaryDecember 30, 2023 | pakistantoday.com.pkPPTI to play its election innings ‘without bat’ on tough pitchDecember 25, 2023 | gulftoday.aeGPTI core committee urges ECP to allocate ‘bat’ symbolDecember 17, 2023 | pakistantoday.com.pkPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesSilver's Options Sizzle: Are Traders Betting on a Breakout?By Jeffrey Neal Johnson | June 5, 2025View Silver's Options Sizzle: Are Traders Betting on a Breakout?The Other AI Chipmaker: Why Marvell's Dip Is a BuyBy Jeffrey Neal Johnson | June 12, 2025View The Other AI Chipmaker: Why Marvell's Dip Is a BuyAT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?By Jeffrey Neal Johnson | June 5, 2025View AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?Reddit Stock Ignites: Surge in Call Options Signals Big BetBy Gabriel Osorio-Mazilli | June 24, 2025View Reddit Stock Ignites: Surge in Call Options Signals Big BetSnowflake Hits 52-Week High—Options Traders Bet on Further RallyBy Gabriel Osorio-Mazilli | June 29, 2025View Snowflake Hits 52-Week High—Options Traders Bet on Further RallyPTI, IFRX, ORMP, ENLV, and AVEO Company DescriptionsAVEO Pharmaceuticals NASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Enlivex Therapeutics NASDAQ:ENLV$1.18 +0.05 (+3.98%) Closing price 07/3/2025 02:39 PM EasternExtended Trading$1.18 0.00 (0.00%) As of 07/3/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.InflaRx NASDAQ:IFRX$0.80 -0.01 (-0.74%) Closing price 07/3/2025 03:37 PM EasternExtended Trading$0.80 0.00 (0.00%) As of 07/3/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Oramed Pharmaceuticals NASDAQ:ORMP$2.18 +0.02 (+1.11%) Closing price 07/3/2025 01:10 PM EasternExtended Trading$2.18 0.00 (-0.14%) As of 07/3/2025 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Proteostasis Therapeutics NASDAQ:PTIProteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
